Updated Insights into Probiotics and Hepatobiliary Diseases
Open Access
- 25 February 2024
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 12 (3) , 515
Abstract
Hepatobiliary diseases have a high prevalence worldwide, with a wide range of diseases involved in the liver and biliary system. Modifications in gut microbiota have been proven to have an association with unbalanced intestinal homeostasis and the dysfunction of host metabolism and the immune system, which can be the risk factors for many hepatobiliary diseases, such as nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), nonalcoholic fatty steatohepatitis (NASH), hepatitis, cirrhosis, hepatocellular carcinoma (HCC) and cholestasis, as well as infection due to liver transplantation. Probiotics are commonly used gut microbiota-targeted strategies to treat dysbiosis and intestinal dysfunction, as well as the gut–liver axis, which can enhance the effectiveness of probiotics in the management of liver diseases. Recent studies have explored more potential single or mixed strains of probiotics, and bioinformatics methods can be used to investigate the potential mechanisms of probiotics on liver diseases. In this review, we summarize the preclinical and clinical studies on the role of probiotics in hepatobiliary diseases from 2018 to 2023, revealing the possible mechanism of probiotics in the treatment of hepatobiliary diseases and discussing the limitations of probiotics in treating hepatobiliary diseases. This review provides updated evidence for the development of probiotic products, exploration of new probiotic strains, and support for clinical studies. Further studies should focus on the safety, viability, and stability of probiotics, as well as medication dosage and duration in clinical practice.Keywords
Funding Information
- Gala Family Trust (200007008, 260007830, 260007482, 15162961, 16172751, 18192141)
- Contract Research (200007008, 260007830, 260007482, 15162961, 16172751, 18192141)
- Health and Medical Research Fund (200007008, 260007830, 260007482, 15162961, 16172751, 18192141)
This publication has 99 references indexed in Scilit:
- Synbiotics, prebiotics and probiotics for people with chronic kidney diseaseCochrane Database of Systematic Reviews, 2023
- Lactobacillus lactis and Pediococcus pentosaceus‐driven reprogramming of gut microbiome and metabolome ameliorates the progression of non‐alcoholic fatty liver diseaseClinical and Translational Medicine, 2021
- Lactobacillus caseiAlleviated the Abnormal Increase of Cholestasis‐Related Liver Indices During Tuberculosis Treatment: A Post Hoc Analysis of Randomized Controlled TrialMolecular Nutrition & Food Research, 2021
- Effect of a Multistrain Probiotic on Cognitive Function and Risk of Falls in Patients With Cirrhosis: A Randomized TrialHepatology Communications, 2019
- Systemic inflammation in decompensated cirrhosis: Characterization and role in acute‐on‐chronic liver failureHepatology, 2016
- Drug-induced cholestasisHepatology, 2011
- Endotoxemia and gut barrier dysfunction in alcoholic liver disease†Hepatology, 2009
- Hepatitis E virus: Molecular virology, clinical features, diagnosis, transmission, epidemiology, and preventionJournal of Medical Virology, 2008
- The increasing prevalence of hepatitis delta virus (HDV) infection in South LondonJournal of Medical Virology, 2007
- Hepatitis C virus: Epidemiology and transmissionHepatology, 1997